Lexapro Market Trends, Market Share, Industry Size, Growth, Opportunities and Market Forecast - 2022 to 2028

The global lexapro market is anticipated to grow at a significant CAGR during the forecast period (2022-2028). Lexapro belongs to a class of drugs known as selective serotonin reuptake inhibitors (SSRI) used to treat depression and anxiety disorders. The rise in the prevalence of anxiety disorders is anticipated to drive the growth of the market. For instance, according to the data published by the Anxiety & Depression Association of America (ADAA) in 2021, anxiety disorders are the most common mental illness in the US, affecting 40 million adults at age 18 years and older, or 18.1% of the population. They are highly treatable, yet only 36.9% of those suffering receive treatment. Generalized Anxiety Disorder (GAD) affects approximately 6.8 million adults or 3.1% of the US population, Panic Disorder (PD) affects 6 million adults or 2.7% of the US population, whereas Society Anxiety Disorder (SAD) affects 15 million adults or 6.8% of the US population.

A full report of Lexapro Market is available at:https://orionmarketreports.com/lexapro-market/96321/  

Thus, as per Anxiety & Depression Association of America (AADA), people with anxiety disorders are three to five times more likely to visit a doctor and six times more likely to be hospitalized for physiatric disorders than those who do not suffer from an anxiety disorder. Thus, the rise in the prevalence of anxiety disorders is anticipated to fuel the demand for the global lexaprotablet market during the forecast period

The rise in the prevalence of depression is further anticipated to drive the growth of the market. According to the data published by the WHO in 2021, depression is the leading cause of disability globally and is a major contributor to the overall global burden of diseases. Depression is a common illness, with an estimated 3.8% population affected including 5.0% among adults and 5.7% among adults older than 65 years. It can cause the affected person to suffer greatly and function poorly at work and in the family. Moreover, depression can also lead to suicide. Over 700,000 mortalities occur due to suicide annually and is registered as the fourth leading cause of death in 15-29 years-olds.

Market Coverage

The market number available for - 2021-2028
Base year- 2021
Forecast period- 2022-2028
Segment Covered-
By Type
By Application
Regions Covered-
North America
Europe
Asia-Pacific
Rest of the World
Competitive Landscape- Lupin Ltd., Novartis International AG, Aurobindo Pharma Ltd., and Xian Janssen Pharmaceutical Ltd. among others

Key questions addressed by the report

What is the market growth rate?
Which segment and region dominate the market in the base year?
Which segment and region will project the fastest growth in the market?
How has COVID-19 impacted the market?
Deviation from the pre-COVID-19 forecast
Most affected region and segment
Who is the leader in the market?
How players are addressing challenges to sustain growth?
Where is the investment opportunity?

Global Lexapro Tablet Market Report by Segment

By Type

Tablet
Solution

By Application

Children
Adults

Media Contact:

Company Name: Orion Market Reports
Contact Person: Mr. Anurag Tiwari
Email: info@orionmarketreports.com
Contact no: +91 780-304-0404

About Us:

Orion Market Reports (OMR) endeavors to provide exclusive blend of qualitative and quantitative market research reports to clients across the globe. Our organization helps both multinational and domestic enterprises to bolster their business by providing in-depth market insights and most reliable future market trends. Our reports address all the major aspects of the markets providing insights and market outlook to global clients.

This release was published on openPR.